Sleep Medicine Reviews
Volume 5, Issue 3 , Pages 207-221 , June 2001

Haematological aspects of obstructive sleep apnoea

References 

  1. Koskenvuo M, Kaprio J, Telakivi T, Partinen M, Heikkilä K, Sarna S. Snoring as a risk factor for ischaemic heart disease and stroke in men. Br Med J. 1987;294:16–19
  2. Berman CL, Yeo EL, Mencel-Drake JD, Rurie BC, Ginsberg MH, Furie B. A platelet alpha granule membrane protein that is associated with the plasma membrane after activation: characterization and sub-cellular localization of platelet activation-dependent granule-external membrane protein. J Clin Invest. 1986;78:130–137
  3. Shattil SJ, Hoxie JA, Cunningham M, Brass LF. Changes in the platelet membrane glycoprotein IIb-IIIa complex during platelet activation. J Biol Chem. 1985;260:11107–11114
  4. Michelson AD, Barnard MR, Ellis PA, Matic GB, Kestin AS. Activation-induced modulation of the platelet surface expression of glycoprotein IV in vitro and in vivo. Thromb Haemost. 1991;1070:A1349
  5. Michelson AD, Ellis PA, Barnard MR, Matic GB, Viles AF, Kestin AS. Downregulation of the platelet surface glycoprotein Ib-IX complex in whole blood stimulated by thrombin, adenosine diphosphate, or in vivo wound. Blood. 1991;77:770–779
  6. Shattil SJ, Cunningham M, Hoxie JA. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood. 1987;70:307–315
  7. Warkentin TE, Powling MJ, Hardisty RM. Measurements of fibrinogen binding to platelets in whole blood by flow cytometry: a micromethod for the detection of platelet activation. Br J Haematol. 1990;76:387–394
  8. Fitzgerald GA, Catella F, Oates JE. Eicosanoid biosynthesis in human cardiovascular disease. Hum Pathol. 1987;18:248–252
  9. Shattil SJ, Budzynski A, Scrutton MC. Epinephrine induces platelet fibrinogen receptor expression, fibrinogen binding and aggregation in whole blood in the absence of other excitatory agonists. Blood. 1989;73:150–158
  10. Lanza F, Beretz A, Stierle A, Hanau D, Kubina M, Cazenave JP. Epinephrine potentiates human platelet activation but is not an aggregating agent. Am J Physiol. 1988;255:H1276–H1288
  11. Hawiger, J, Steer, ML, Salzman, EW, Intracellular regulatory processes in platelets. In: Colman RW, Hirsch J, Marder VJ, Salzman EW (eds) Hemostasis and thrombosis: principles and clinical practice. Philadelphia: JB Lippincott Co, 1987
  12. Hjemdahl, P, Physiology of the autonomous nervous system as related to cardiovascular function: implications for stress research. In: Byrne DG, Roseman RH (eds) Anxiety and the heart. New York: Hemisphere Publishing Corp, 1990
  13. Wedzicha JA, Syndercombe-Court D, Tan KC. Increased platelet aggregate formation in patients with chronic airflow obstruction and hypoxemia. Thorax. 1991;46:504–507
  14. Maly J, Pecka M, Pinterova E, Pidrman V, Blaha M, Siroky O, et al. Changes in platelet function in patients with arterial hypertension. Vnitr Lek. 1995;41:458–461
  15. Polasek J, Richardson M, Moore MA, Blajchman MA. Evidence for an alternative mechanism of human platelet secretion involving peripheralization of secretory granules and formation of membrane-associated multivesicular structures. Thromb Res. 1987;45:771–782
  16. Thaulow E, Erikssen J, Sandvik L, Stormorken H, Cohn PF. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation. 1991;84:613–617
  17. Ellis SG, Roubin GS, King SB, Douglas JS, Weintraub WS, Thomas RG, et al. Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty. Circulation. 1988;77:372–379
  18. Hamm CW, Lorenz RL, Bleifeld W, Kupper W, Wober W, Weber PC. Biochemical evidence of platelet activation in patients with unstable angina. J Am Coll Cardiol. 1987;10:998–1006
  19. Carlson JT, Hedner JA, Ejnell H, Peterson LE. High prevalence of hypertension in sleep apnea patients independent of obesity. Am J Respir Crit Care Med. 1994;150:72–77
  20. Shattil SJ, Budzynski A, Scrutton MC. Epinephrine induces platelet fibrinogen receptor expression, fibrinogen binding and aggregation in whole blood in the absence of other excitatory agonists. Blood. 1989;73:150–158
  21. Fletcher EC, Miller J, Schaaf JW, Fletcher JG. Urinary catecholamines before and after tracheostomy in patients with obstructive sleep apnea and hypertension. Sleep. 1987;10:35–44
  22. Nobili LS, Schiavi G, Bozano E, De Carli F, Ferrillo F, Nobili F. Morning increase of whole blood viscosity in obstructive sleep apnea syndrome. Clin Hemorheol Microcirculation. 2000;22:21–27
  23. Chin K, Ohi M. New insights into the therapy and pathophysiology of patients with obstructive sleep apnoea syndrome. Respirology. 1998;3:139–143
  24. Rangemark C, Hedner JA, Carlson JT, Gleerup G, Winther K. Platelet function and fibrinolytic activity in hypertensive and normotensive sleep apnea patients. Sleep. 1995;18:188–194
  25. Kimura H, Niijima M, Abe Y, Edo H, Sakabe H, Kojima A, et al. Compensatory excretion of prostacyclin and thromboxane metabolites in obstructive sleep apnea syndrome. Intern Med. 1998;37:127–133
  26. Krieger J, Benzoni D, Sforza E, Sassard J. Urinary excretion of prostanoids during sleep in obstructive sleep apnoea patients. Clin Exp Pharmacol Physiol. 1991;18:551–555
  27. Bokinsky G, Miller M, Ault K, Husband P, Mitchel J. Spontaneous platelet activation and aggregation during obstructive sleep apnea and its response to therapy with nasal continuous positive airway pressure. A preliminary investigation. Chest. 1995;108:625–630
  28. Eisensehr I, Ehrenberg BL, Noachtar S, Korbett K, Byrne A, McAuley A, et al. Platelet activation, epinephrine, and blood pressure in obstructive sleep apnea syndrome. Neurology. 1998;51:188–195
  29. Winther K, Hillegass W, Tofler GH, Jimenez A, Brezinski DA, Schafer AI, et al. Effects on platelet aggregation and fibrinolytic activity during upright posture and exercise in healthy men. Am J Cardiol. 1992;70:1051–1055
  30. Figures WR, Scearce LM, Wachtvogel Y, Chen J, Colman RF, Colman RW. Platelet ADP receptor and alpha2-adrenoceptor interaction. J Biol Chem. 1986;261:5981–5986
  31. Lacombe C, Da Silva JL, Bruneval P, Fournier JG, Wendling F, Casadevall N, et al. Peritubular cells are the site of erythropoietin synthesis in murine hypoxic kidney. J Clin Invest. 1988;81:620–623
  32. Silverstein A, Gilbert H, Wasserman LR. Neurologic complications of polycythemia. Ann Intern Med. 1962;57:909–916
  33. Dormandy JA. The influence of hemorheology on the practice of clinical medicine. Ric Clin Lab. 1983;13(Suppl. 3):7–27
  34. Carlson JT, Hedner J, Fagerberg B, Ejnell H, Magnusson B, Fyhrquist F. Secondary polycythaemia associated with nocturnal apnoea – a relationship not mediated by erythropoietin?. J Int Med. 1992;231:381–387
  35. Moore-Gillon JC, Treacher DF, Gaminara EJ, Pearson TC, Cameron IR. Intermittent hypoxia in patients with unexplained polycythaemia. Br Med J. 1986;293:588–590
  36. Messinezy M, Aubry S, O»Connel G, Treacher DF, Pearson TC. Oxygen desaturation in apparent and relative polycythaemia. Br Med J. 1991;302:216–217
  37. Knaupp W, Khilnani S, Sherwood J, Scharf S, Steinberg H. Erythropoietin response to acute normobaric hypoxia in humans. J Appl Physiol. 1992;73:837–840
  38. Hoffstein V, Herridge M, Mateika S, Redline S, Strohl KP. Hematocrit levels in sleep apnea. Chest. 1994;106:787–791
  39. Saarelainen S, Hasan J, Seppala E. Effect of nasal CPAP treatment on plasma volume, aldosterone and 24-h blood pressure in obstructive sleep apnoea. J Sleep Res. 1996;5:181–185
  40. Sanner B, Konermann C, Doberauer F, Laschewski F, Kreuzer I. Auswirkungen einer nCPAP Therapie auf das Blutbild bei Patienten mit einer obstruktiven Schlafapnoe. Pneumologie. 1995;49:413–417
  41. Krieger J, Sforza E, Delanoe C, Petiau C. Decrease in hematocrit with continuous positive airway pressure treatment in obstructive sleep apnoea patients. Eur Respir J. 1992;5:228–233
  42. Chin K, Ohi M, Noguchi T, Otsuka N, Tsuboi T, Mishima M, et al. Effects of NCPAP therapy on fibrinogen levels in obstructive sleep apnea syndrome. Am J Respir Crit Care Med. 1996;153:1972–1976
  43. Krieger J, Sforza E, Barthelmebs M, Imbs JL, Kurtz D. Overnight decrease in hematocrit after nasal CPAP treatment in OSA patients. Chest. 1990;97:729–730
  44. Goldman JM, Ireland RM, Berthon-Jones M, Grunstein RR, Sullivan CE, Biggs JC. Erythropoietin concentrations in obstructive sleep apnoea. Thorax. 1991;46:25–27
  45. Cahan C, Decker MJ, Arnold JL, Washington LH, Veldhuis JD, Goldwasser E, et al. Diurnal variations in serum erythropoietin levels in healthy subjects and sleep apnea patients. J Appl Physiol. 1992;72:2112–2117
  46. McKeon JL, Saunders NA, Murree-Allen K, Olson LG, Gyalay S, Dickeson J, et al. Urinary uric acid: creatinine ratio, serum erythropoietin, and blood 2,3-diphosphoglycerate in patients with obstructive sleep apnea. Am Rev Respir Dis. 1990;142:8–13
  47. Cahan, C, Decker, M, Strohl, KP, Humoral correlates of sleep apnoea: erythropoietin and hypoxemia. In: Issa FG (ed.) Sleep and Respiration. New York: Wiley-Liss Inc, 1990
  48. Pokala P, Llanera M, Sherwood J, Scharf S, Steinberg H. Erythropoietin response in subjects with obstructive sleep apnea. Am J Respir Crit Care Med. 1995;15:1862–1865
  49. Cahan C, Decker MJ, Arnold JL, Goldwasser E, Strohl KP. Erythropoietin levels with treatment of obstructive sleep apnea. J Appl Physiol. 1995;79:1278–1285
  50. Krieger J. Regulation of plasma volume during obstructive sleep apnoea. J Sleep Res. 1995;4(Suppl. 1):107–111
  51. Ehlenz K. Regulation of blood volume-implications for cardiovascular pathophysiology in sleep apnoea. J Sleep Res. 1995;4(Suppl. 1):30–33
  52. Rodenstein DO, D»Odemont JP, Pieters T, Aubert-Tulkens G. Diurnal and nocturnal diuresis and natriuresis in obstructive sleep apnea. Effects of nasal continuous positive airway pressure therapy. Am Rev Respir Dis. 1992;145:1367–1371
  53. Krieger J, Laks L, Wilcox I, Grunstein RR, Costas LJV, McDougall JG, et al. Atrial natriuretic peptide release during sleep in patients with obstructive sleep apnoea before and during treatment with nasal continuous positive airway pressure. Clin Sci. 1989;77:407–411
  54. Krieger J, Follenius M, Sforza E, Brandenberger G, Peter JD. Effects of treatment with continuous positive airway pressure on atrial natriuretic peptide and arginine vasopressin release during sleep in patients with obstructive sleep apnoea. Clin Sci. 1991;80:443–449
  55. Krieger J, Schmidt M, Sforza E, Lehr L, Imbs JL, Coumaros G, et al. Urinary excretion of guanosine 3′:5′-cyclic monophosphate during sleep in obstructive sleep apnoea patients with and without nasal continuous positive airway pressure treatment. Clin Sci. 1989;76:31–37
  56. Ichioka M, Hirata Y, Inase N, Tojo N, Yoshizawa M, Chida M, et al. Changes of circulating atrial natriuretic peptide and antidiuretic hormone in obstructive sleep apnea syndrome. Respiration. 1992;59:164–168
  57. Ehlenz K, Peter JH, von Wichert P, Kaffarnik H. Einfluß der Schlafapnoe auf volumenregulierende Hormonsysteme Hinweise für Komplexe Störungen der Volumenregulation. Z Kardiol. 1991;80 (Suppl. 8):97–98
  58. Lin CC, Tsan KW, Lin CY. Plasma levels of atrial natriuretic factor in moderate to severe obstructive sleep apnea syndrome. Sleep. 1993;16:37–39
  59. Baruzzi A, Riva R, Cirignotta F, Zucconi M, Capelli M, Lugaresi E. Atrial natriuretic peptide and cateÍcholamines in obstructive sleep apnea syndrome. Sleep. 1991;14:83–86
  60. Singer DRJ, Dean JW, Buckley MG, Sagnella GA, MacGregor GA. Secretion of atrial natriuretic peptide from the heart in man. Br Heart J. 1987;58:24–28
  61. Warley ARH, Fontes F, Wilson M, Raine AE, Stradling JR. Lack of effect of an inspiratory threshold load on plasma atrial natriuretic peptide levels. Clin Sci. 1990;78:311–313
  62. Warley ARH, Stradling JR. Abnormal diurnal variation in salt and water excretion in patients with obstructive sleep apnoea. Clin Sci. 1988;74:183–185
  63. Krieger J, Imbs JL, Schmidt M, Kurtz D. Renal function in patients with obstructive sleep apnoea-effects of nasal continuous positive airways pressure. Arch Intern Med. 1988;148:1337–1340
  64. Krieger J, Sforza E, Barthelmebs M, Imbs JL, Lehr L, Coumaros G, et al. Renal function and sleep apnea syndromes. Neurophysiol Clin. 1989;19:199–207
  65. Follenius M, Krieger J, Krauth MO, Sforza F, Brandenberger G. Obstructive sleep apnea treatment: peripheral and central effects on plasma renin activity and aldosterone. Sleep. 1991;14:211–217
  66. Larsen E, Celi A, Gilbert GE, Furie BC, Erban JK, Bonfanti R, et al. PADGEM protein: a receptor that mediates the interaction of activated platelets with neutrophils and monocytes. Cell. 1989;59:305–312

PII: S1087-0792(01)90158-3

doi: 10.1053/smrv.2001.0158

Sleep Medicine Reviews
Volume 5, Issue 3 , Pages 207-221 , June 2001

Article Tools